<DOC>
	<DOCNO>NCT00910624</DOCNO>
	<brief_summary>This single-arm , multicenter study boceprevir ( BOC ) combination peginterferon plus ribavirin ( PEG/RBV ) adult chronic hepatitis C ( CHC ) genotype 1 participant complete per-protocol defined treatment achieve sustain viral response ( SVR ) PEG/RBV control arm ( ) Schering-Plough Research Institute ( SPRI ) study BOC combination therapy . Participants able enroll study within 2 week last dose PEG/RBV previous protocol receive BOC+ PEG/RBV 44 week follow 24 week post-treatment follow-up . Participants able enroll study within 2 week last dose PEG/RBV previous protocol receive PEG/RBV 4 week follow BOC+ PEG/RBV 44 week , 24 week post-treatment follow-up .</brief_summary>
	<brief_title>Boceprevir Treatment Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders Peginterferon/Ribavirin ( P05514 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participant must assign PEG/RBV control arm previous SPRI study BOC , must complete treatment per protocol , compliant study treatment schedule procedure within previous study . Participant must receive least 12 week treatment PEG/RBV must discontinue treatment previous study due futility rule ( define previous protocol ) , virologic breakthrough , relapse . Participant must detectable HCVRNA upon completion previous study . Participant participant partner ( ) must agree use acceptable method contraception least 2 week prior start study treatment continue least 6 month last dos study drug , longer dictate local regulation . Participant must willing give write informed consent . All participant exclusion criterion SPRI clinical study participant participate prior qualify study apply study , EXCEPT follow : Treatment RBV within 90 day interferonalpha within 1 month enrollment exclusionary P05514 . Participation SPRI clinical trial within 30 day enrollment study exclusionary . Use growth factor entry study allow prescribe previous study . Laboratory criterion thyroidstimulating hormone ( TSH ) apply . Laboratory criterion hemoglobin , neutrophil , platelet apply , unless meet dose reduction/interruption/discontinuation criterion previous study . Participants develop moderate depression previous study continue stable well control exclude Participants opportunity receive boceprevir previous study . Participants require discontinuation , interruption , dose reduction RBV 2 week previous study . Participants require discontinuation , interruption , dose reduction PEG le twothirds assign start dose 2 week previous study . Participants experience lifethreatening SAE consider least possibly relate study drug investigator sponsor previous study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>